RetinalGeniX Technologies Inc. announced the launch of an Institutional Review Board (IRB) for research on its DNA/GPS program. The study aims to offer recommendations for enhancing the preselection process and management of ocular injections. The proposed patient selection process has the potential to reduce the cost and improve the safety and efficacy of patient candidate selection for ocular injections.

These factors represent significant challenges associated with wet macular degeneration-related vision loss.